Arterial hypertension and Alzheimer’s disease. Prologue to neurodegeneration
https://doi.org/10.18705/1607-419X-2019-25-2-122-133
Abstract
Cognitive impairment is a global medical and social problem. Alzheimer’s disease (AD) is the most common disease leading to the development of cognitive impairment and dementia. Arterial hypertension (HTN) is considered to be the strongest risk factor for the development of both vascular dementia and AD. Recent studies have demonstrated the importance of the glymphatic system in removing β-amyloid from the brain through the perivascular Virchow–Robin spaces. The interest is that the adequate functioning of the glymphatic system mainly depends on the level of blood pressure during the day and the quality of sleep. In this article, we will consider the main mechanisms of the HTN influence on the glymphatic system, brain substance-related damage and the development of cognitive impairment.
About the Authors
V. Yu. Lobzin
Kirov Military Medical Academy
Russian Federation
Russian Federation
MD, PhD, DSc, Professor, Department of Neurology Diseases
6, lit. G Akademician Lebedev str., St Petersburg, 194044 Russia
K. A. Kolmakova
Kirov Military Medical Academy
Russian Federation
Russian Federation
MD, Neurologist, Neurology Clinics
6, lit. G Akademician Lebedev str., St Petersburg, 194044 Russia
A. Yu. Emelin
Kirov Military Medical Academy
Russian Federation
Russian Federation
MD, PhD, DSc, Professor, Deputy Head, Department of Neurology Diseases
6, lit. G Akademician Lebedev str., St Petersburg, 194044 Russia
S. N. Yanishevskiy
Kirov Military Medical Academy,
Almazov National Medical Research Centre
Russian Federation
Russian Federation
MD, PhD, DSc, Professor, Department of Neurology Diseases
6, lit. G Akademician Lebedev str., St Petersburg, 194044 Russia
St Petersburg, Russia
References
1. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. Br Med J. 2001;322(7300):1447–1451.
2. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes and Alzheimer’s disease. J Alzheimer’s Dis. 2009;16(4):693–704.
3. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010;75(13):1195–1202.
4. Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension. 2013;62(5):810–817.
5. Kaffashian S, Dugravot A, Nabi H, Batty GD, Brunner E, Kivimäki M et al. Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. Eur Heart J. 2011;32(18):2326–2332.
6. Diener HC. Prevention of dementia should start 20 years before symptoms become apparent. Eur Heart J. 2011;32(18):2228–2230.
7. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723–738.
8. Qiu L, Ng G, Tan EK, Liao P, Kandiah N, Zeng L. Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer’s disease mice. Sci Rep. 2016;6:23964.
9. Bennett SA, Pappas BA, Stevens WD, Davidson CM, Fortin T, Chen J. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging. 2000;21(2):207–214.
10. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathol. 2009;118(1): 87–102.
11. Hughes TM, Craft S, Lopez OL. Review of the potential role of arterial stiffness in the pathogenesis of Alzheimer’s disease. Neurodegener Dis Manag 2015;5:121–135.
12. Elkins JS, Yaffe K, Cauley JA, Fink HA, Hillier TA, Johnston SC. Pre-existing hypertension and the impact of stroke on cognitive function. Ann Neurol. 2005;58(1):68–74.
13. Varakin YuYa. Stroke prevention. Essays of anioneurology, Ed. by ZA Suslin. M.: Atmosphera, 2005. 368 p. In Russian.
14. de Leeuw FE, van Gijn J. Vascular dementia. Pract Neurol. 2003;3:86–91.
15. Gorelick PB. Blood pressure and the prevention of cognitive impairment. J Am Med Assoc Neurol. 2014;71(10):1211–1213.
16. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487–499.
17. Bellew KM, Pigeon JG, Stang PE, Fleischman W, Gardner RM, Baker WW. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 2004;18(4):208–213.
18. Starr JM, Whalley LJ, Inch S, Shering PA. Blood pressure and cognitive function in healthy old people. J Am Geriatr Soc. 1993;41(7):153–156.
19. Moonga I, Niccolini F, Wilson H, Pagano G, Politis M, Alzheimer’s Disease Neuroimaging Initiative. Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer’s disease. Eur J Neurol. 2017;24 (9):1173–1182. doi:10.1111/ene.13374
20. Verechshagin NV, Morgunov VA, Gulevskaya TS. Brain pathology of atherosclerosis and hypertension. M., 1997; 288 p. In Russian.
21. Laman JD, Weller RO. Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J Neuroimmune Pharmacol. 2013;8(4):840–856.
22. Gurol ME, Viswanathan A, Gidicsin C, Hedden T, Martinez-Ramirez S, Dumas A et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol. 2013;73(4):529–536.
23. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66 (1):23–29.
24. Iliff JJ, Nedergaard M. Is there a cerebral lymphatic system? Stroke. 2013;44(6):93–95.
25. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373–377. doi:10.1126/science.1241224
26. Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W et al. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer’s disease. Mol Med. 2003; 9(3–4):112–122.
27. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. 2009;8(7):643–653.
28. Zhu YC, Tzourio C, Soumare A, Mazoyer B, Dufouil C, Chabriat H. Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI Markers of small vessel disease: a population-based study. Stroke. 2010;41(11):2483–2490.
29. Chen HF, Chang-Quan H, You C, Wang ZR, Hui W, Liu QX et al. The circadian rhythm of arterial blood pressure in Alzheimer disease (AD) patients without hypertension. Blood Press. 2012;22(2): 101–105.
30. Salles GF, Reboldi G, Fagard RH, Cardoso CR, Pierdomenico SD, Verdecchia P et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: The Ambulatory Blood Pressure Collaboration in Patients with Hypertension (ABC-H) Meta-Analysis. Hypertension. 2016;67(4):693–700.
31. Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension. 2000;35(3):844–851. doi:10.1161/01.HYP.35.3.844
32. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55–61. doi:10.1161/HYPERTENSIONAHA.107.100727
33. O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension. 2005;46(1):200–204.
34. Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J Hypertens. 2008;26(8):1636–1641.
35. Bellelli G, Frisoni GB, Lucchi E, Guerini F, Geroldi C, Magnifico F et al. Blunted reduction in night-time blood pressure is associated with cognitive deterioration in subjects with longstanding hypertension. Blood Press Monit. 2004;9(2):71–76.
36. van Boxtel MP, Henskens LH, Kroon AA, Hofman PA, Gronenschild EH, Jolles J et sl. Ambulatory blood pressure, asymptomatic cerebrovascular damage and cognitive function in essential hypertension. J Hum Hypertens. 2006;20(1):5–13.
37. Guo H, Tabara Y, Igase M, Yamamoto M, Ochi N, Kido T et al. Abnormal nocturnal blood pressure profile is associated with mild cognitive impairment in the elderly: the J‑SHIPP study. Hypertens Res. 2010;33(1):32–36.
38. Mestre H, Tithof J, Du T, Song W, Peng W, Sweeney AM et al. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nat Commun. 2018;9(1):4878. doi:10.1038/s41467-018-07318-3
39. Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31 (10):1925–1938.
40. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31 (7):1281–1357.
41. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(Suppl 5): S7–S10.
42. Poluektov MG, Levin YaI. Insomnia, somnology and sleep medicine. Selected lectures. Ed. By YaI Levin and MG Poluektov. M.: Medforum-alfa, 2013. P. 192–220. In Russian.
43. Kovalzon VM. Physiology and neurochemistry of the cycle wakefulness — sleep. M.: BINOM, Knowledge laboratory, 2012. 240 p. In Russian.
44. Somers VK, Dyken ME, Mark AL, Abboud FM. Sympatheticnerve activity during sleep in normal subjects. New Eng J Med. 1993;328(5):303–307. doi:10.1056/nejm199302043280502
45. Hanak V, Somers VK. Cardiovascular and cerebrovascular physiology in sleep. Sleep Disorders. 2011:98;315–325. doi:10.1016/b978-0-444-52006-7.00019-8
46. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer’s disease — friend or foe? Trends in Neurosciences. 2009:32 (12):619–628. doi:10.1016/j.tins.2009.07.006
Review
For citations:
Lobzin V.Yu., Kolmakova K.A., Emelin A.Yu., Yanishevskiy S.N. Arterial hypertension and Alzheimer’s disease. Prologue to neurodegeneration. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2019;25(2):122-133. (In Russ.) https://doi.org/10.18705/1607-419X-2019-25-2-122-133
Views:
2044
Email this article 